All In Biotech

Drug Trial Radar · NCT00777244

Efficacy of Adjuvant Mitotane Treatment (ADIUVO)

Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence

Last checked: Nov 20, 2026Latest source record: May 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Apr 2008

Primary completion

Dec 2018

Study completion Dec 2020

Sponsor

Lead sponsor
University of Turin, ItalyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 22, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study Rationale Adrenocortical carcinoma (ACC) is a very rare disease with a high risk of relapse after radical surgery. The efficacy of adjuvant mitotane treatment is suggested by a retrospective multicenter international study showing that postoperative mitotane treatment was associated with a significant reduction of the risk of relapse and death. However, these promising results need confirmation in a randomized prospective study. Caution should be adopted particularly in patients with low risk of disease relapse, in whom the benefit of therapy should be weighted against the side effects. Even if an adjuvant treatment seems justified in patients at high risk of relapse, a randomised prospective study is needed to assess whether such a treatment is efficacious in patients at low-intermediate risk. The purpose of the present study is to determine whether adjuvant mitotane treatment is effective in prolonging the disease free survival in patients with adrenocortical carcinoma at low-intermediate risk of progression who underwent radical resection

Conditions

  • Adrenocortical Carcinoma

Interventions

  • MITOTANEDrug

    mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease Free survivalTime frame: Till the last follow up

Locations

28 sites in 7 countries. Site status is shown where the registry gives one.

  • Medical Oncology Branch - Center for Cancer Research - National Cancer Institute

    Bethesda, Maryland · Recruiting

  • Endocrine Oncology - University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan · Active not recruiting

  • Endocrinologie - Centre hospitalier de l'Université de Montréal (CHUM)

    Montreal, Canada · Recruiting

  • Endocrinologie - CHU Besançon Hôpital Jean Minjoz

    Besançon, France · Recruiting

  • Endocrinologie - CHU Lyon Hôpital Pierre Wertheimer

    Bron, France · Recruiting

  • Endocrinologie - Hôpital A. Michallon

    La Tronche, France · Recruiting

  • Endocrinologie - Cochin, APHP

    Paris, France · Recruiting

  • Endocrinologie - CHU Toulouse Hôpital Larrey

    Toulouse, France · Recruiting

  • Endocrinologie - Institut de Cancérologie Gustave Roussy

    Villejuif, France · Recruiting

  • University Hospital Campus Mitte Charitè, Berlin

    Berlin, Germany · Recruiting

  • University Hospital of Dresden

    Dresden, Germany · Recruiting

  • University Hospital of Düsseldorf

    Düsseldorf, Germany · Not yet recruiting

  • Center for Endocrine Tumors - ENDOC

    Hamburg, Germany · Recruiting

  • University Medicin Centre of Munchen

    München, Germany · Recruiting

  • University Hospital Wuerzburg, Endocrinology

    Würzburg, Germany · Recruiting

  • UO Oncologia Medica - AO Spedali Civili

    Brescia, Italy · Recruiting

  • Università degli studi di Firenze

    Florence, Italy · Not yet recruiting

  • Azienda Ospedaliera di Foggia

    Foggia, Italy · Active not recruiting

  • Ospedale Cà Granda-Niguarda-Milano

    Milan, Italy · Recruiting

  • Azienda Ospedaliera San Luigi

    Orbassano, Italy · Recruiting

  • Department of Clinical and Biological Sciences, University of Turin, Internal Medicine 1

    Orbassano, Italy · Recruiting

  • Azienda Ospedaliera Padova

    Padova, Italy · Active not recruiting

  • Università degli studi di Palermo

    Palermo, Italy · Not yet recruiting

  • Policlinico Universitario A. Gemelli

    Roma, Italy · Active not recruiting

  • A.O.U. San Giovanni Battista - Molinette

    Torino, Italy · Recruiting

  • A.O.Universitaria Arcispedale S.Anna Ferrara

    Ferrara, Fe, Italy · Recruiting

  • Dept. of Internal Medicine Maxima Medisch Centrum

    Eindhoven, Netherlands · Recruiting

  • Cancer Research UK Clinical Trials Unit (CRCTU) - School of Cancer Sciences - University of Birmingham

    Birmingham, Edgbaston, United Kingdom · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.